目的 探討骨康膠囊聯(lián)合阿法骨化醇片治療老年骨質(zhì)疏松的臨床療效。方法 選取2015年9月-2016年9月京東中美醫(yī)院收治的老年骨質(zhì)疏松患者117例為研究對(duì)象，按隨機(jī)數(shù)字表法將患者分為對(duì)照組（58例）和治療組（59例）。對(duì)照組口服阿法骨化醇片，1片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服骨康膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療6個(gè)月。觀察兩組的臨床療效，比較兩組的骨密度、骨代謝和生活質(zhì)量。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.76%、96.61%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組腰椎L₂~L₄和髖部骨密度均顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組骨密度明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清骨鈣素（BGP）、血清堿性磷酸酶（BALP）、酒石酸酸性磷酸酶5b（TRACP-5b）水平均顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些骨代謝生化指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組健康狀況調(diào)查問卷（SF-36）評(píng)分均顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組SF-36評(píng)分明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 骨康膠囊聯(lián)合阿法骨化醇片治療老年骨質(zhì)疏松具有較好的臨床療效，可調(diào)節(jié)骨代謝，提高骨密度，改善患者的生活質(zhì)量，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To discuss the clinical efficacy of Gukang Capsules combined with Alfacalcidol Tablets in treatment of senile osteoporosis. Methods Patients (117 cases) with senile osteoporosis in Jingdong Zhongmei Hospital from September 2015 to September 2016 were randomly divided into the control group (58 cases) and the treatment group (59 cases). Patients in the control group were po administered with Alfacalcidol Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Gukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and bone mineral density, bone metabolism, and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.76% and 96.61%, respectively, and there was difference between two groups (P < 0.05). After treatment, lumbar vertebra L₂-L₄ and hip bone mineral density in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of BGP, BALP, and TRACP-5b in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the SF-36 score in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). Conclusion GuKang Capsules combined with Alfacalcidol Tablets has clinical curative effect in treatment of senile osteoporosis, can regulate the bone metabolism, increase the bone mineral density, and improve the quality of life, which has a certain clinical application value.